Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030, marking its largest strategic investment since entering the market in 1993, aimed at expanding its pharmaceutical production and R&D footprint [2][4] Group 1: Investment Details - The investment will cover the entire value chain from drug discovery, clinical development to manufacturing, enhancing AstraZeneca's capabilities in cell therapy and antibody-drug conjugates [4][5] - The investment will significantly deepen AstraZeneca's R&D presence in China, linking over 500 clinical hospitals with its global strategic R&D centers in Beijing and Shanghai [4][5] - AstraZeneca's collaboration with CSPC Pharmaceutical Group could reach up to 18.5 billion USD (approximately 128.5 billion RMB), with an initial payment of 1.2 billion USD (approximately 8.4 billion RMB) [3][5] Group 2: Market Dynamics - China's pharmaceutical market is undergoing structural changes, with a record 76 innovative drugs approved by the National Medical Products Administration in 2025, indicating a trend towards diversified innovative therapies [3][6] - Approximately one-third of global licensing transactions are related to Chinese biopharmaceutical companies, with over 30% of clinical trials in cutting-edge fields like cell therapy and ADCs occurring in China [3][6] Group 3: Strategic Partnerships - AstraZeneca has formed partnerships with leading biotech companies in China, aiming to leverage local innovations and enhance global supply chains [5][6] - The company has engaged in 17 licensing collaborations with 15 Chinese partners since 2023, with contract values exceeding 10 billion USD in 2025 alone [5][6] Group 4: Innovation and Development - The investment aligns with China's "Healthy China 2030" initiative, focusing on improving disease prevention, early screening, and accessibility of innovative drugs [10][12] - AstraZeneca's R&D pipeline in China has grown significantly, with over 200 projects, and is expected to yield around 20 new drug approvals by 2030 [7][9] Group 5: Industry Impact - AstraZeneca's investment reflects the ongoing opening of the Chinese pharmaceutical market, supported by favorable policies and reforms that enhance the R&D environment [7][10] - The company has invested in 31 Chinese innovative enterprises through its medical industry fund, facilitating 17 global licensing collaborations worth over 13.7 billion USD [9][10]

作为日产中国管理委员会主席、东风汽车有限公司总裁，马智欣明确表示，日产在中国的战略核心可概 括为 "在中国、为中国、向全球"。他强调，日产将依托中国在新能源和智能化领域的领先优势，加速 产品迭代："到2027年夏季，我们投放的新能源车型将从8款增至10款，其中9款为日产品牌车型。今天 展出的N7和Frontier Pro PHEV，未来都将出口全球，实现本土研发生产与全球市场共享。" 针对新能源研发投入，马智欣透露，未来3年东风日产计划投入100亿元，扩建技术中心至容纳4000名员 工，并将研发周期压缩至24个月："我们充分授权本地团队主导车型开发，在坚守日产安全质量标准的 前提下，实现'中国速度'的突破。" 这一策略打破了传统合资企业依赖总部决策的模式，凸显对中国市 场敏捷响应的决心。 凤凰网科技《浪潮对话》出品 在2025年上海车展期间，日产汽车多位高管围绕中国市场战略、新能源产品布局、本地化创新等核心议 题接受了凤凰网科技等媒体的专访，一场持续45分钟的访谈，揭开了这家日系车企在中国市场的战略转 型密码。 面对中国新能源渗透率突破42%的市场格局，日产汽车宣布到2027年夏季，将其新能源产品投放计划从 ...